Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

ALX Oncology Holdings Inc. (ALXO)

0.4605
-0.0236
(-4.84%)
As of 12:02:22 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Cost of Revenue
--
--
--
0
0
Gross Profit
--
--
--
0
0
Operating Expense
142,467
142,467
170,278
127,436
83,555
Operating Income
-142,467
-142,467
-170,278
-127,436
-83,555
Net Non Operating Interest Income Expense
7,637
7,637
9,084
4,040
78
Other Income Expense
-20
-20
389
-22
-7
Pretax Income
-134,850
-134,850
-160,805
-123,418
-83,484
Tax Provision
0
0
0
64
-21
Net Income Common Stockholders
-134,850
-134,850
-160,805
-123,482
-83,463
Diluted NI Available to Com Stockholders
-134,850
-134,850
-160,805
-123,482
-83,463
Basic EPS
-2.58
--
-3.74
-3.03
-2.07
Diluted EPS
-2.58
--
-3.74
-3.03
-2.07
Basic Average Shares
52,174.9040
--
42,987.7670
40,699.6120
40,308.0500
Diluted Average Shares
52,174.9040
--
42,987.7670
40,699.6120
40,308.0500
Total Operating Income as Reported
-142,467
-142,467
-170,278
-127,436
-83,555
Total Expenses
142,467
142,467
170,278
127,436
83,555
Net Income from Continuing & Discontinued Operation
-134,850
-134,850
-160,805
-123,482
-83,463
Normalized Income
-134,850
-134,850
-160,805
-123,482
-83,463
Interest Income
9,366
9,366
10,649
4,278
91
Interest Expense
1,729
1,729
1,565
238
13
Net Interest Income
7,637
7,637
9,084
4,040
78
EBIT
-133,121
-133,121
-159,240
-123,180
-83,471
EBITDA
-132,249
-132,249
-158,404
-122,838
-83,420
Reconciled Cost of Revenue
--
--
--
0
0
Reconciled Depreciation
872
872
836
342
51
Net Income from Continuing Operation Net Minority Interest
-134,850
-134,850
-160,805
-123,482
-83,463
Total Unusual Items Excluding Goodwill
--
--
--
0
0
Total Unusual Items
--
--
--
0
0
Normalized EBITDA
-132,249
-132,249
-158,404
-122,838
-83,420
Tax Rate for Calcs
0
0
0
0.0002
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/17/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GBIO Generation Bio Co.
0.3707
-4.94%
 
ZNTL Zentalis Pharmaceuticals, Inc.
1.2750
+3.66%
 
FDMT 4D Molecular Therapeutics, Inc.
3.2300
+3.69%
 
CGEM Cullinan Therapeutics, Inc.
7.74
+0.52%
 
STOK Stoke Therapeutics, Inc.
8.93
+3.12%
 
ORIC ORIC Pharmaceuticals, Inc.
5.28
+12.23%
 
NKTX Nkarta, Inc.
1.8950
+1.34%
 
NRIX Nurix Therapeutics, Inc.
9.59
+3.12%
 
ANNX Annexon, Inc.
1.7100
+1.18%
 
VOR Vor Biopharma Inc.
0.1600
-70.12%